1. Hepatosplenic T‐cell lymphoma, immunosuppressive agents and biologicals: what are the risks?. Issue 3 (March 2014) Authors: Subramaniam, K.; Yeung, D.; Grimpen, F.; Joseph, J.; Fay, K.; Buckland, M.; Talaulikar, D.; Elijah, J.; Clarke, A. C.; Pavli, P.; Moore, J. Journal: Internal medicine journal Issue: Volume 44:Issue 3(2014) Page Start: 287 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY. (23rd June 2022) Authors: Matasar, M.; Bartlett, N. L.; Sehn, L. H.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; Ku, M.; Nastoupil, L. J.; Wei, M. C.; Yin, S.; To, I.; Turner, D.; Huang, H.; Min, J.; Penuel, E.; Budde, L. E. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1016 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PHASE 2 STUDY OF PARSACLISIB (INCB050465) FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) (CITADEL‐202). (12th June 2019) Authors: Belada, D.; Fay, K.; Casasnovas, R.; Gressin, R.; Lee, H.; Mehta, A.; Munoz, J.; Verhoef, G.; Corrado, C.; DeMarini, D.; Zhao, W.; Chen, X.; Coleman, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 326 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Primary central nervous system posttransplantation lymphoproliferative disorder after heart and lung transplantation. Issue 5 (May 2015) Authors: Gifford, G.; Fay, K.; Jabbour, A.; Ma, D. D. Journal: Internal medicine journal Issue: Volume 45:Issue 5(2015) Page Start: 583 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗